NEW YORK (GenomeWeb News) – PerkinElmer this week announced the establishment of direct operations in Israel, headquartered near Tel Aviv. Through its new Israel base, PerkinElmer will commercialize and support its life sciences and technologies, analytical sciences, and laboratory services business offerings.

The company's board separately last week declared a quarterly dividend of $.07 per share, payable on Nov. 8 to shareholders of record at the close of business on Oct. 18.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.